Effects of short-term add-on ezetimibe to statin treatment on expression of adipokines and inflammatory markers in diabetic and dyslipidemic patients
Cardiovasc Ther
; 35(6): 12307-12307, 2017.
Article
in English
| Sec. Est. Saúde SP, SESSP-IDPCPROD, Sec. Est. Saúde SP
| ID: biblio-1061822
Responsible library:
BR79.1
Localization: BR79.1
ABSTRACT
AIM:
The influence of short-term add-on ezetimibe to simvastatin treatment on expression of adipokines and inflammatory markers was investigated in diabetic and nondiabetic patients with hypercholesterolemia.METHOD:
Hypercholesterolemic nondiabetic (HC, n = 37) and diabetic (DM, n = 47) patients were treated with simvastatin (SV, 10 or 20 mg/d/8-wk) and then SV plus ezetimibe (SV + EZ, 10 mg each/d/4 wk). Serum lipids, glycemic profile, and inflammatory markers (hsCRP, adiponectin, resistin, VCAM-1, and ICAM-1) were evaluated before and after the add-on ezetimibe therapy. mRNA expression of ADIPOR1, ADIPOR2, RETN, VCAM1, and ICAM1 was measured by real-time PCR in peripheral blood mononuclear cells (PBMC).RESULTS:
Serum concentrations of LDL and HDL cholesterol, and adiponectin were higher in HC than DM patients (P < .05). The add-on ezetimibe therapy reduced total and LDL cholesterol, apoB and adiponectin serum levels in HC and DM groups, and resistin in HC subjects (P < .05). DM patients showed higher expression of ADIPOR1, ADIPOR2, RETN, and VCAM1 in PBMC than subjects in HC group, before and after add-on ezetimibe therapy (P < .05). PBMC RETN mRNA expression was reduced by add-on ezetimibe therapy in HC individuals (P < .05), but not in DM subjects...
Search on Google
Collection:
National databases
/
Brazil
Database:
Sec. Est. Saúde SP
/
SESSP-IDPCPROD
Main subject:
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/
Diabetes Mellitus
/
Dyslipidemias
/
Adipokines
/
Ezetimibe
Language:
English
Journal:
Cardiovasc Ther
Year:
2017
Document type:
Article
Institution/Affiliation country:
Center of Excellence in Translational Medicine, CETM-BIOREN, Department of Basic Sciences, Universidad de La Frontera/CL
/
Department of Clinical and Toxicological Analysis, School of Pharmaceutical Sciences, University of Sao Paulo/BR
/
Instituto Dante Pazzanese de cardiologia/BR
/
University Hospital, University of Sao Paulo/BR